Drug
Amphetamine clinical trials
Also written Adzenys XR-ODT.
- studies test it
- 16
- open now
- 1
- in phase 3
- 2
- first study started
- 2004
Keep track of what changes. Save the Amphetamine studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Brand
Combined with it in one product
Studies by the year they started
16 studies that test it; most in 2018 (3)
| Year | Studies |
|---|---|
| 2004 | 1 |
| 2007 | 1 |
| 2008 | 1 |
| 2011 | 1 |
| 2012 | 2 |
| 2013 | 1 |
| 2016 | 1 |
| 2017 | 2 |
| 2018 | 3 |
| 2019 | 2 |
| 2024 | 1 |
By phase
A phase 1/2 study counts in both.
- Early Phase 1
- 1
- Phase 1
- 2
- Phase 2
- 4
- Phase 3
- 2
- Phase 4
- 5
- No phase
- 3
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 8 · Other 8
Tris Pharma, Inc. (3) · Arbor Pharmaceuticals, Inc. (2) · Shire (1) · Neurocrine Biosciences (1) · University of California, San Diego (1) · Yale University (1) · University Hospital, Basel, Switzerland (1) · Emory University (1)
Often tested with
Tested in the same studies.
Guanfacine (1) · TAK-041 (1) · Raclopride c-11 (1) · Dasb C-11 (1) · Lysergic Acid Diethylamide (1) · N-Methyl-3,4-methylenedioxyamphetamine (1) · Carbidopa, levodopa drug combination (1) · Methylphenidate (1)
Studies
Open first, then newest update. How each study uses Amphetamine is read from its arms, and is right about nine times in ten.
Testing it · 16
- A Trial of Dyanavel XR in Treating Co-occurring Fatigue Symptoms in Adults With Attention Deficit Hyperactivity Disorder (ADHD).RecruitingPhase 4Rochester Center for Behavioral MedicineNCT06248229Written as Dyanavel XR
- ADZENYS XR-ODT™ in Children (4 to <6 Years) Diagnosed With Attention-deficit/Hyperactivity DisorderWithdrawnPhase 4Aytu BioPharma, Inc.NCT07169162Written as ADZENYS XR-ODT
- Adult Attention Deficit Hyperactivity Disorder (ADHD) Study With Amphetamine SulfateCompletedPhase 3Arbor Pharmaceuticals, Inc.NCT03659929Written as Amphetamine Sulfate
- Impact of Combined Medication and Behavioral Treatment for ASD & ADHDTerminatedPhase 2Duke UniversityNCT03242772Written as Amphetamine
- Amphetamine Extended Release Tablets and Driving Performance in Subjects With Attention Deficit/Hyperactivity Disorder (ADHD)CompletedPhase 2Tris Pharma, Inc.NCT04027361Written as Amphetamine Extended Release (ER) Tablet 20 mg
- Safety and Tolerability of SPD503 and Psychostimulants in Children and Adolescents Aged 6-17 With Attention-Deficit/Hyperactivity Disorder (ADHD)CompletedPhase 2ShireNCT00151996Written as Amphetamine + SPD503
- A Single-Dose Positron Emission Tomography (PET) Study to Determine the Effect of TAK-041 on Amphetamine-Induced Dopamine Release in the Central Nervous System (CNS)CompletedPhase 1Neurocrine BiosciencesNCT02959892Written as Amphetamine
- Crossover Study to Evaluate the Efficacy of AR11 in Pediatric Patients With ADHD in a Laboratory Classroom SettingCompletedPhase 4Arbor Pharmaceuticals, Inc.NCT01986062Written as AR11
- Monoamine Contributions to Neurocircuitry in Eating DisordersCompletedPhase 4University of California, San DiegoNCT02020408Written as amphetamine
- Test-retest Reproducibility of [11C]PHNO PET Using the Constant Infusion ParadigmCompletedNot applicableYale UniversityNCT01699607Written as Amphetamine
- Dyanavel® XR Extended-Release Oral Suspension in the Treatment of Children With ADHD: A Laboratory School StudyCompletedPhase 3Tris Pharma, Inc.NCT03088267Written as amphetamine extended-release oral suspension, 2.5 mg/mL
- Pharmacokinetic Study of DYANAVEL XR (Amphetamine) Extended-release Oral Suspension, in Children Aged 4 to 5 YearsCompletedPhase 4Tris Pharma, Inc.NCT03610464Written as Amphetamine Extended Release Suspension [Dyanavel]
- Role of Dopamine, Serotonin and 5-HT2A Receptors in Emotion ProcessingCompletedEarly Phase 1University Hospital, Basel, SwitzerlandNCT03019822Written as Amphetamine
- Neurobiological Principles Applied to the Rehabilitation of Stroke PatientsCompletedNot applicableEmory UniversityNCT00715520Written as Amphetamine Sulfate
- Stimulant Enhancement of Well-Being Therapy for DepressionTerminatedNot applicableMassachusetts General HospitalNCT01478113Written as Amphetamine/dextroamphetamine
- Caffeine and CocaineCompletedPhase 1/2Virginia Commonwealth UniversityNCT00733993Written as Amphetamine
Codes
What other systems call Amphetamine · ClinicalTrials.gg INT006962
- MeSH (NLM) D000661AmphetamineConfirmed ClinicalTrials.gov, NLM, Wikidata
- UNII (FDA) CK833KGX7EAMPHETAMINEConfirmed FDA, NLM, Wikidata
- RxNorm 725Confirmed FDA, Wikidata
- Wikidata Q179452DL-amphetamineConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C62006AmphetamineOne source FDA
- DrugBank DB00182One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | D000661 | Amphetamine | Confirmed ClinicalTrials.gov, NLM, Wikidata |
| UNII (FDA) | CK833KGX7E | AMPHETAMINE | Confirmed FDA, NLM, Wikidata |
| RxNorm | 725 | — | Confirmed FDA, Wikidata |
| Wikidata | Q179452 | DL-amphetamine | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C62006 | Amphetamine | One source FDA |
| DrugBank | DB00182 | — | One source Wikidata |
Also registered as amphetamine sulfate (UNII 6DPV8NK46S · RxNorm 81952).
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.